SemBioSys Signs Contract Manufacturing Agreement for Plant-Produced Insulin With Cangene.

PR Newswire Europe, November, 2006

CALGARY, Canada, November 22 /PRNewswire/ --

- Canadian Biotechnology Company Secures Manufacturing Partner to Supply Insulin in Preparation for Preclinical and Clinical Development

SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today announced the completion of a Technology Transfer and Manufacturing Agreement with Cangene Corporation, a biopharmaceutical company and contract manufacturing organization, for the processing and purification of SemBioSys' plant-produced insulin. The contract is part of the Company's preparations for its Investigational New Drug Application (IND) and the initiation of clinical trials. Cangene will manufacture...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement